Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
Program reduces ER admissions and inpatient costs
Mendenhall M et al. Quality Care Symposium, Abstract 30
Key clinical point: An initiative designed to reduce avoidable emergency room visits and hospitalizations reduced both admissions and inpatient costs.
Major finding: The program cut admissions by 16% and saved nearly $3.2 million in Medicare costs savings over the course of a year.
Study details: Analysis of first-year experience including 1,600 patients per quarter for a large, independent, community-based oncology practice participating in the Oncology Care Model (OCM) of the Centers for Medicare and Medicaid Services.
Disclosures: Authors on the study provided disclosures related to Janssen Oncology, Pfizer, Amgen, Abbvie, Merck, Pharmacyclics, Bristol-Myers Squibb, Celgene, Genentech/Roche, AZTherapies, Lilly, and Oncology Hematology Care/US Oncology.
Mendenhall M et al. Quality Care Symposium, Abstract 30.